A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Nearly one million people in the U.S. are living with Parkinson's Disease. Playhouse Square is rolling out a new program to ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

With their help, we were able to identify a specific TMEM16F mutation which is common in Ashkenazi Jews in general ... new ...

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not respond to levodopa, the main treatment for Parkinson's disease. Therefore, the ...

According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...

The University of Pittsburgh was awarded $8 million to continue researching a new therapy for Parkinson's patients.

Parkinson’s Disease (PD) is a common brain disorder that affects movement and is most often linked with aging. It’s the second most common age-related brain disease, affecting millions worldwide.

Designed for patients, caregivers, and anyone interested in Parkinson’s disease, this free event is open to the public with ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.

The drug works by essentially forcing our cells to "spit out" dangerous protein clumps involved in Alzheimer's.